

1 Full title: Acute kidney injury outcomes of COVID-19 confirmed patients in a

2 Philippine tertiary hospital: A retrospective study

3 Short title: Acute kidney injury outcomes in COVID-19

4 Author list: Joberly Sayson,<sup>1\*</sup> Reginald Kalaw,<sup>1¶</sup> Bernadette Ecunar Ordon, <sup>1¶</sup>

5 Marissa Elizabeth Lim<sup>1¶</sup>

6

7 <sup>1</sup>Section of Nephrology, Department of Internal Medicine, East Avenue Medical

8 Center, Quezon City, Metro Manila,

9 ¶ These authors contributed equally to this work.

10

11 Corresponding author

12 Joberly Sayson

13 Email: [joberly\\_sayson@yahoo.com](mailto:joberly_sayson@yahoo.com)

14

15

16

17

18

19

20

21

22

23

24

25

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

26

27 **Abstract**

28 The novel coronavirus (COVID-19) is known to be the fifth pandemic causing  
29 massive deaths worldwide. This virus has not only been deeply associated with acute  
30 respiratory distress, but also acute kidney injury (AKI). This study describes the  
31 baseline characteristics and various outcomes of AKI based on the KDIGO 2012  
32 Clinical Practice Guidelines in patients hospitalized with COVID-19 at a Philippine  
33 tertiary hospital. A total of 195 patient records were retrospectively reviewed for the  
34 study. Of the 195 patients, 81(42%) patients developed AKI. Significant baseline  
35 characteristics included older age ( $56.28 \pm 14.12$ ), presence of hypertension  
36 ( $p=0.004$ ), diabetes mellitus ( $p=0.002$ ), and cardiovascular disease ( $p=0.003$ ). Also,  
37 the use of diuretics, inotropes and antibiotics were more prevalent in patients who  
38 developed AKI. Most of the patients who had AKI were categorized as stage 1  
39 (49.38%). Mechanical ventilation was significantly ( $p<0.001$ ) more prevalent in  
40 patients with AKI (20.99%) compared to patients without AKI (5.26%). There was  
41 significantly higher rates ( $p<0.001$ ) of renal replacement therapy in patients with AKI  
42 (30.86%). Lastly, higher mortality rates were observed in patients with AKI (50.62%)  
43 versus patients without AKI (12.28%). Our study demonstrated that patients with  
44 COVID-19 can develop AKI and tend to have a poorer prognosis.

45

46

## 47 **Introduction**

48           At the end of 2019, cases of a novel human pneumonia were first reported in  
49 Wuhan, China where patients reported symptoms of malaise, dry cough, dyspnea, and  
50 fever, with some requiring intensive care for severe and acute respiratory distress. The  
51 coronavirus disease of 2019 (COVID-19) quickly spread worldwide becoming the  
52 fifth recognized pandemic following the 1918 flu contagion [1]. The World Health  
53 Organization (WHO) reports that the number of COVID-19 cases has peaked at 767  
54 million, with approximately 7 million deaths around the world since the start of the  
55 pandemic [2]. In the Philippines, the cumulative cases rose to more than 4 million  
56 with over 66,000 total deaths [2].

57           The coronaviruses are large, enveloped, single-stranded RNA viruses usually  
58 found in mammals such as dogs, cats, and humans. They cause neurologic,  
59 respiratory, and gastrointestinal diseases [3]. The Severe Acute Respiratory  
60 Syndrome Coronavirus-2 (SARS-CoV-2), in particular, is known to target the  
61 epithelial cells and pneumocytes of the nasal and bronchial areas through the viral  
62 structural spike (S) protein that binds to angiotensin-converting enzyme 2 (ACE 2)  
63 receptor [4]. Viral uptake is facilitated by cleaving the ACE 2 and activating the S  
64 protein of the virus [4]. Once within the cell, it promotes a cascade of events that  
65 trigger the inflammatory response, resulting in the disruption of the epithelial–  
66 endothelial integrity of the lungs. This eventually leads to acute respiratory distress  
67 syndrome (ARDS) [5].

68           In the kidneys, the virus can directly damage the renal tubular epithelium and  
69 podocytes through the ACE 2-dependent pathway. Viral invasion results in  
70 mitochondrial dysfunction, collapsing glomerulopathy, acute tubular necrosis, and  
71 protein leakage in the Bowman’s Capsule leading to acute kidney injury (AKI) [6].

72 These processes along with other factors, such as sepsis, hypovolemia, and  
73 cardiorenal syndrome, amplify the insult to the kidneys [7]. COVID-19 is also known  
74 to activate cytokine release syndrome (CRS), a phenomenon associated with the  
75 release of pro-inflammatory cytokines, such as interleukin-6, which could lead to  
76 systemic endothelial injury further impacting the kidneys [8]. Another mechanism  
77 that is known to be contributory is the organ crosstalk occurring between the  
78 cardiopulmonary system and the kidneys [9]. Hypoxemia resulting from ARDS and  
79 hypoperfusion due to COVID-19-related cardiac pathology may result in further  
80 damage to the renal tubules [10].

81 A meta-analysis of 44 studies conducted by Sabaghian et al reported AKI  
82 incidence to be as high as 56.2% in hospitalized COVID-19 patients and 75.5% after  
83 admission. The median age was reported to be 63 years, and over 40% had an existing  
84 comorbidity, such as CKD, chronic obstructive pulmonary disease, hypertension,  
85 diabetes, and tumors [11]. Proteinuria of any degree, hematuria of any degree,  
86 elevated baseline blood urea nitrogen (BUN), serum creatinine, peak serum creatinine  
87 > 133  $\mu\text{mol/l}$ , and AKI over stage 2 were associated with in-hospital death after  
88 adjusting for age, sex, disease severity, comorbidities, and lymphocyte count [11].  
89 Various studies have established the intrinsic association of AKI with poor prognosis  
90 (i.e., up to 83% at 5 years) and higher risk for mortality immaterial of pre-AKI  
91 baseline (hazard ratio [HR] 1.08 to 4.59) or recovery of renal function (HR 1.08 to  
92 5.75) [12]. However, in patients with COVID-19 and AKI, there appears to be a 13-  
93 fold increased risk of mortality [13] with an estimated overall hospital mortality rate  
94 of 66.2% [11]. Among the several reasons for higher mortality were severe sepsis-  
95 related multi-organ failure, direct kidney involvement, and acute respiratory distress  
96 syndrome [14].

97 AKI in some COVID–19–confirmed patients may prompt the need for renal  
98 replacement therapy (RRT) or even a kidney transplant. The impact of these outcomes  
99 is more apparent in resource-limited settings, such as in the Philippine healthcare  
100 system [15]. AKI in COVID-19 encumbers the healthcare system by directly affecting  
101 the efficient utilization of hemodialysis machines, staff, and other hospital resources.  
102 Also, long-term monitoring is needed to avoid the progression of AKI to chronic  
103 kidney disease (CKD) and reduce the associated mortality in high-risk populations  
104 [15]. As such, it is important to recognize means to promptly identify and prevent  
105 further renal injury and facilitate recovery of renal function in patients with and who  
106 are recovering from COVID-19 [16].

107 In this study, we aimed to determine the clinical outcomes of patients who  
108 developed AKI in a tertiary hospital setting in the Philippines based on the Kidney  
109 Disease Improving Global Outcomes (KDIGO) 2012 Clinical Practice Guidelines  
110 AKI classification system. We sought to identify the baseline demographic profile of  
111 COVID-19 patients and determine the outcome in those who develop AKI and at  
112 what stage could lead to poorer outcomes. With this, we hope that our clinicians be  
113 guided in their clinical approach and prognostication of patients with greater risk for  
114 AKI to reduce or shorten the need for RRT and avoid complications like prolonged  
115 hospitalizations, development of CKD, as well as death.

## 116 **Materials and methods**

### 117 **Study design**

118 This is a retrospective cohort study that included a review of charts of all  
119 confirmed COVID-19 patients based on the result of their reverse transcription  
120 polymerase chain reaction (RT-PCR) test from 1 March 2020 to 31 December 2020.  
121 Baseline data, including age, co-morbidities, admission serum BUN and creatinine,

122 urinalysis, and urine output monitoring were obtained. Data on medications during the  
123 hospital stay of the patients were also gathered. Outcomes such as discharge, death,  
124 and the need for assisted ventilation (e.g., high-flow nasal cannula, or mechanical  
125 ventilation) were collected (**Fig. 1**).

126 Patients who decided to go home against medical advice, had no baseline  
127 (within 24 hours upon admission) serum BUN and creatinine measurements, had  
128 undergone maintenance hemodialysis before admission, and had a history of urinary  
129 tract obstruction before admission were excluded.

### 130 **Sampling and sample size**

131 A minimum of 185 patients were required for this study based on a 3.1%  
132 prevalence of AKI among patients with COVID-19 disease [17], and a 5% level of  
133 significance, and a 2.5% desired width of a confidence interval were set. A purposive  
134 sampling technique was employed with a total of 195 patients enrolled.

### 135 **Data gathering and ethical considerations**

136 The study was submitted to the East Avenue Medical Center (EAMC)  
137 Institutional Ethics Review Board (IERB) for approval prior to the actual data  
138 collection and was conducted in compliance with the Philippine Data Privacy Act of  
139 2012. A waiver of informed consent was requested and granted by the IERB. Only the  
140 primary investigator was involved in the collection of data. Patients included in the  
141 study were anonymized in the data collection form and only the case number and code  
142 numbers were used. General data, clinical features and laboratory results were  
143 extracted from the charts and recorded. The data gathered were then stored in a  
144 password-protected computer and stored in a lock and key cabinet. Data will be  
145 disposed via the secure delete feature as included in the operating system of the

146 computer and documents used will be subjected to paper shredding 3 years after study  
147 initiation.

148 The list of COVID–19–confirmed patients from March 2020 to December  
149 2020 was obtained from the Public Health Unit of a Philippine tertiary hospital, the  
150 EAMC in Quezon City. After, the charts of these patients were retrieved from the  
151 Medical Records for data collection. Baseline demographics such as age, gender, and  
152 co-morbidities such as hypertension, diabetes mellitus, and cardiac diseases, were  
153 documented. Serum BUN and creatinine levels determined within 24 hours of  
154 admission, as well as AKI findings during their hospital stay, were obtained, and  
155 classified based on the criteria of the KDIGO guidelines. Urinalysis and urine output  
156 monitoring were part of the data collection form. Medications given to the patients  
157 while admitted were likewise noted.

158 Patients were classified according to whether they developed AKI, whether  
159 they were discharged, expired, whether they required a high-flow nasal cannula or a  
160 mechanical ventilator, and their length of stay at the hospital recorded.

### 161 **Data processing and statistical analysis**

162 Descriptive statistics were used to summarize the demographic and clinical  
163 characteristics of the patients. Frequency and proportion were used for categorical  
164 variables, median and interquartile range for non-normally distributed continuous  
165 variables and mean and SD for normally distributed continuous variables. An  
166 independent sample T-test, Mann-Whitney U test, and Fisher’s Exact/Chi-square test  
167 were used to determine the difference in mean, rank, and frequency, respectively,  
168 between the control and experimental groups. All statistical tests were two-tailed  
169 tests. The Shapiro-Wilk test was used to evaluate the normality of the continuous  
170 variables. Missing values were neither replaced nor estimated. The null hypotheses

171 were rejected at a 0.05 level of significance. Lastly, the Stata 13.1 program was used  
172 for data analysis.

### 173 **Results**

174 Patients with AKI were significantly older ( $56.28 \pm 14.12$ ;  $P < 0.001$ ) compared  
175 with patients without AKI ( $47.91 \pm 14.72$ ). There was no significant difference in the  
176 rates of AKI between male and female genders. Additionally, comorbidities, such as  
177 hypertension ( $p = 0.004$ ), diabetes mellitus ( $p = 0.002$ ), and cardiovascular disease  
178 ( $p = 0.003$ ), were significantly more prevalent in patients with AKI compared to  
179 patients without AKI, at 58.02% vs. 36.84%, 32.1 vs. 13.16%, 20.99 vs. 6.14%,  
180 respectively. Baseline creatinine clearance based on the Chronic Kidney Disease  
181 Epidemiology Collaboration (CKD-EPI) criteria showed that an estimated glomerular  
182 filtration rate (eGFR) of  $>90$  ( $p < 0.001$ ) was significantly associated with AKI.  
183 Diuretics ( $p = 0.001$ ), inotropes ( $p = 0.001$ ), and the use of antibiotics were more  
184 prevalent in patients who developed AKI vs. non-AKI patients (34.57% vs. 13.16%,  
185 20.99% vs. 5.26% and 100% vs. 85.09%, respectively).

186  
187 Table 2 shows urinalysis results in patients with AKI vs. non-AKI, namely, the  
188 macroscopic and microscopic findings, chemical tests, and presence of crystals.  
189 Microscopic analysis reveals that AKI patients had significantly higher rates of hazy  
190 to turbid urine ( $p = 0.042$ ) vs. non-AKI patients. The presence of blood was likewise  
191 significantly higher ( $p = 0.047$ ) in those with AKI vs. non-AKI. The existence of  
192 bacteria ( $p = 0.038$ ) and amorphous urates ( $p = 0.001$ ) between AKI and non-AKI  
193 patients were also significantly different.

194  
195 Table 3 outlines that out of the 195 subjects reviewed, 81 developed AKI, the  
196 majority of whom developed stage 1 AKI. Table 4 shows the different outcomes in



197 patients who developed AKI vs. those who did not develop AKI. There was  
198 significantly ( $p<0.001$ ) greater mortality in patients with AKI (50.62%) vs. patients  
199 without AKI (12.28%). The length of hospital stay was not significant between AKI  
200 and non-AKI patients with an average hospital stay of 21 days. There was no  
201 significant difference among patients hooked to nasal cannula, facemask, or high-flow  
202 nasal cannula between AKI and non-AKI individuals. Mechanical ventilation was  
203 significantly ( $p<0.001$ ) more prevalent in patients with AKI (20.99%) compared to  
204 patients without AKI (5.26%). There were significantly ( $p<0.001$ ) more RRT cases in  
205 patients with AKI (30.86%) vs. patients without AKI (1.75%). The two patients who  
206 had undergone RRT without the development of AKI were those who had undergone  
207 isolated ultrafiltration while on hemoperfusion.

208 Table 5 demonstrates that there were more mortalities in stage 3 AKI while  
209 more discharges were observed in stage 1 AKI. The length of hospital stay was  
210 similar for the three stages. Most patients who had undergone RRT are in AKI stage  
211 3, the seven patients who underwent RRT for stage 1 and stage 2 were patients who  
212 had undergone hemoperfusion, overlapping with hemodialysis.

213

## 214 **Discussion**

215 Our study has outlined the number of patients who developed AKI, their  
216 baseline characteristics, outcomes, and those who underwent RRT in patients  
217 admitted for COVID-19 at the EAMC from March to December 2020. The EAMC is  
218 one of the largest hospitals to admit COVID-19 patients in Metro Manila. Of the 195  
219 patients included in the study, 81 (41.5%) of them developed AKI. These findings  
220 mirror the results of a US study where 49.3% of patients who had COVID-19  
221 developed AKI [18]. Out of the 81 patients in our study who developed AKI, a

222 majority (49.38%) developed stage 1, followed by the development of stage 3 which  
223 is 35.8%, and lastly by stage 2 which is 14.81%.

224 Several studies have confirmed that age is a factor for the development of AKI  
225 in COVID-19. For instance, in the study of Nimkar and colleagues, it was shown that  
226 the median age of the patients was 71 years [19] while it was 61 years old for the  
227 study of Fominsky et al [20]. Most individuals admitted for COVID-19 at our center  
228 tended to be older ( $56.28 \pm 14.12$ ). The significant comorbidities include  
229 hypertension, diabetes mellitus and cardiovascular diseases (58.02%, 32.1% and  
230 20.99% respectively). This is consistent with the study conducted by Sargiacomo et al  
231 associating worse outcomes with these comorbid illnesses and they represent risk  
232 factors for the development of AKI [21].

233 Several factors may predispose the critically ill to the development of AKI in  
234 COVID-19. Hypoperfusion of the kidneys secondary to shock resulting from sepsis,  
235 hypovolemia, or cardiogenic etiologies, especially in patients with underlying cardiac  
236 disease, may be one of the causes [22]. On the other hand, pre-existing COPD was not  
237 seen as a predisposing factor in our study. As for medications used at the time of  
238 admission, diuretics, inotropes, and antibiotics tended to be more significantly  
239 prevalent in patients who developed AKI compared with other medications such as  
240 steroids, ACEi/ARBs, antivirals and NSAIDs. In a study by Nadim et al, the  
241 medications that were found to be contributory to AKI development include  
242 antibiotics, contrast media, and NSAIDs. They attributed the development of AKI  
243 acute tubular injury [23].

244 Cheng et al observed that hematuria and proteinuria were associated with a  
245 threefold and almost twofold increase in the risk of AKI in COVID-19 patients;  
246 however, this was not replicated in our study [24]. We do note that urine transparency

247 and the microscopic presence of red blood cells (RBCs) are associated with AKI. In a  
248 Turkish study, histopathological findings in kidneys of COVID-19 patients include  
249 the presence of viral particles in the proximal tubules, podocytes with varying degrees  
250 of acute tubular necrosis and loss of brush borders, vacuolar degeneration and the  
251 accumulation of RBCs [25], possibly supporting these findings.

252 Patients who developed AKI tended to have poorer prognosis with most of  
253 them succumbing to death (50.62% vs. 12.28%). This is more apparent in those who  
254 developed AKI stage 3 (72.41% vs. 27.59%). Like the systematic review by Ali et al,  
255 mortality was significantly higher in patients with AKI [26]. The length of hospital  
256 stay appears to have no bearing on the development of AKI in COVID-19.

257 Organ crosstalk appears to be the mechanism implicated in the involvement  
258 between alveolar and tubular damage as they are both contributory to interleukin-6  
259 (IL-6) overproduction [9]. This may be the underlying reason for the association  
260 between mechanical ventilation and AKI. Aside from organ crosstalk, pulmonary  
261 inflammation may lead to the release of pro-apoptotic and pro-inflammatory  
262 substances that may lead to AKI [22].

263 Most importantly, out of our 81 patients who developed AKI, 25 underwent  
264 RRT (30.9%) where 18 had stage 3 AKI while seven underwent RRT while  
265 undergoing hemoperfusion. Because of this, we reiterate the importance of close  
266 monitoring in patients with AKI to prevent the need for RRT.

267 We acknowledge that our study has some limitations. Firstly, our analysis was  
268 limited to a retrospective cohort and as such, comes with the limitations inevitably  
269 linked with this type of study. Secondly, laboratory findings, such as urinalysis results  
270 were not uniformly available in all patients, while serum creatinine and blood urea

271 nitrogen (BUN) levels were not regularly monitored. Lastly, no post discharge follow-  
272 up was conducted in our study.

273

## 274 **Conclusions**

275 Our study demonstrated that patients with COVID-19 can develop AKI and  
276 tend to have a poorer prognosis, including death, especially at stage 3 AKI. Older age,  
277 the presence of hypertension, diabetes mellitus, and cardiovascular disease can be risk  
278 factors for the development of AKI as well as the use of diuretics, inotropes, and  
279 antibiotics. The development of AKI in COVID-19 patients can lead to RRT and  
280 monitoring renal function after recovery from AKI is important to avoid progression  
281 to chronic renal failure.

282

## 283 **Acknowledgments**

284 We thank our mentors and colleagues at the Section of Nephrology of the  
285 EAMC for their support and guidance.

286

## 287 **References**

- 288 1. Liu YC, Kuo RL, Shih SR. COVID-19: The first documented coronavirus  
289 pandemic in history. *Biomed J.* 2020;43: 328-333. Epub 20200505. doi:  
290 10.1016/j.bj.2020.04.007
- 291 2. World Health Organization. WHO Coronavirus (COVID-19) Dashboard  
292 [Internet]. Available from: <https://covid19.who.int/>.
- 293 3. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC.  
294 Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019  
295 (COVID-19): A review. *JAMA.* 2020;324: 782-793. doi: 10.1001/jama.2020.12839

- 296 4. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S,  
297 et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a  
298 clinically proven protease inhibitor. *Cell*. 2020;181: 271-280 e278. Epub 20200305.  
299 doi: 10.1016/j.cell.2020.02.052
- 300 5. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings  
301 of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir*  
302 *Med*. 2020;8: 420-422. Epub 20200218. doi: 10.1016/S2213-2600(20)30076-X
- 303 6. Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. Renal histopathological  
304 analysis of 26 postmortem findings of patients with COVID-19 in China. *Kidney Int*.  
305 2020;98: 219-227. Epub 20200409. doi: 10.1016/j.kint.2020.04.003
- 306 7. Ronco C, Bellomo R, Kellum JA. Acute kidney injury. *Lancet*. 2019;394:  
307 1949-1964. doi: 10.1016/S0140-6736(19)32563-2
- 308 8. Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for  
309 extracorporeal therapies. *Nat Rev Nephrol*. 2020;16: 308-310. doi: 10.1038/s41581-  
310 020-0284-7
- 311 9. Panitchote A, Mehkri O, Hastings A, Hanane T, Demirjian S, Torbic H, et al.  
312 Factors associated with acute kidney injury in acute respiratory distress syndrome.  
313 *Ann Intensive Care*. 2019;9: 74. Epub 20190701. doi: 10.1186/s13613-019-0552-5
- 314 10. Ahmadian E, Hosseiniyan Khatibi SM, Razi Soofiyan S, Abediazar S, Shoja  
315 MM, Ardalan M, et al. COVID-19 and kidney injury: Pathophysiology and molecular  
316 mechanisms. *Rev Med Virol*. 2021;31: e2176. Epub 20201006. doi:  
317 10.1002/rmv.2176
- 318 11. Sabaghian T, Kharazmi AB, Ansari A, Omidi F, Kazemi SN, Hajikhani B, et  
319 al. COVID-19 and acute kidney injury: A systematic review. *Front Med (Lausanne)*.  
320 2022;9: 705908. Epub 20220404. doi: 10.3389/fmed.2022.705908

- 321 12. Sawhney S, Mitchell M, Marks A, Fluck N, Black C. Long-term prognosis  
322 after acute kidney injury (AKI): what is the role of baseline kidney function and  
323 recovery? A systematic review. *BMJ Open*. 2015;5: e006497. Epub 20150106. doi:  
324 10.1136/bmjopen-2014-006497
- 325 13. Hansrivijit P, Qian C, Boonpheng B, Thongprayoon C, Vallabhajosyula S,  
326 Cheungpasitporn W, et al. Incidence of acute kidney injury and its association with  
327 mortality in patients with COVID-19: a meta-analysis. *J Investig Med*. 2020;68:  
328 1261-1270. Epub 20200712. doi: 10.1136/jim-2020-001407
- 329 14. Chen YT, Shao SC, Lai EC, Hung MJ, Chen YC. Mortality rate of acute  
330 kidney injury in SARS, MERS, and COVID-19 infection: a systematic review and  
331 meta-analysis. *Crit Care*. 2020;24: 439. Epub 20200716. doi: 10.1186/s13054-020-  
332 03134-8
- 333 15. Tannor EK, Bajpai D, Nlandu YM, Wijewickrama E. COVID-19 and kidney  
334 disease: Progress in health inequity from low-income settings. *Semin Nephrol*.  
335 2022;42: 151318. Epub 20230116. doi: 10.1016/j.semnephrol.2023.151318
- 336 16. Rudd KE, Cizmeci EA, Galli GM, Lundeg G, Schultz MJ, Papali A. Pragmatic  
337 recommendations for the prevention and treatment of acute kidney injury in patients  
338 with COVID-19 in low- and middle-income countries. *Am J Trop Med Hyg*.  
339 2021;104: 87-98. Epub 20210111. doi: 10.4269/ajtmh.20-1242
- 340 17. Kutluhan MA, Tas A, Sahin A, Urkmez A, Topaktas R, Atac O, et al.  
341 Assessment of clinical features and renal functions in Coronavirus disease-19: A  
342 retrospective analysis of 96 patients. *Int J Clin Pract*. 2020;74: e13636. Epub  
343 20200907. doi: 10.1111/ijcp.13636
- 344 18. Pelayo J, Lo KB, Bhargav R, Gul F, Peterson E, DeJoy Iii R, et al. Clinical  
345 characteristics and outcomes of community- and hospital-acquired acute kidney injury

- 346 with COVID-19 in a US inner city hospital system. *Cardiorenal Med.* 2020;10: 223-  
347 231. Epub 20200618. doi: 10.1159/000509182
- 348 19. Nimkar A, Naaraayan A, Hasan A, Pant S, Durdevic M, Suarez CN, et al.  
349 Incidence and risk factors for acute kidney injury and its effect on mortality in  
350 patients hospitalized from COVID-19. *Mayo Clin Proc Innov Qual Outcomes.*  
351 2020;4: 687-695. Epub 20200719. doi: 10.1016/j.mayocpiqo.2020.07.003
- 352 20. Fominskiy EV, Scandroglio AM, Monti G, Calabro MG, Landoni G,  
353 Dell'Acqua A, et al. Prevalence, characteristics, risk factors, and outcomes of  
354 invasively ventilated COVID-19 patients with acute kidney injury and renal  
355 replacement therapy. *Blood Purif.* 2021;50: 102-109. Epub 20200713. doi:  
356 10.1159/000508657
- 357 21. Sargiacomo C, Sotgia F, Lisanti MP. COVID-19 and chronological aging:  
358 senolytics and other anti-aging drugs for the treatment or prevention of corona virus  
359 infection? *Aging (Albany NY).* 2020;12: 6511-6517. Epub 20200330. doi:  
360 10.18632/aging.103001
- 361 22. See YP, Young BE, Ang LW, Ooi XY, Chan CP, Looi WL, et al. Risk factors  
362 for development of acute kidney injury in COVID-19 patients: A retrospective  
363 observational cohort study. *Nephron.* 2021;145: 256-264. Epub 20210329. doi:  
364 10.1159/000514064
- 365 23. Nadim MK, Forni LG, Mehta RL, Connor MJ, Jr., Liu KD, Ostermann M, et  
366 al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute  
367 Disease Quality Initiative (ADQI) Workgroup. *Nat Rev Nephrol.* 2020;16: 747-764.  
368 Epub 20201015. doi: 10.1038/s41581-020-00356-5

- 369 24. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease  
370 is associated with in-hospital death of patients with COVID-19. *Kidney Int.* 2020;97:  
371 829-838. Epub 20200320. doi: 10.1016/j.kint.2020.03.005
- 372 25. Ertuğlu LA, Kanbay A, Afşar B, Elsürer Afşar R, Kanbay M. COVID-19 and  
373 acute kidney injury. *Tuberk Toraks.* 2020;68: 407-418. doi: 10.5578/tt.70010
- 374 26. Ali H, Daoud A, Mohamed MM, Salim SA, Yessayan L, Baharani J, et al.  
375 Survival rate in acute kidney injury superimposed COVID-19 patients: a systematic  
376 review and meta-analysis. *Ren Fail.* 2020;42: 393-397. doi:  
377 10.1080/0886022x.2020.1756323
- 378  
379  
380  
381



382 **Figure legends**

383 **Figure 1. Subject selection process**

384 This figure outlines a summary of our study's inclusion and exclusion process and

385 demonstrates the clinical outcomes of COVID-19 patients admitted at the EAMC.

386

387 **Tables**

388 **Table 1. Baseline Characteristics of COVID-19 Confirmed Patients**

	<b>Total (n=195)</b>	<b>With AKI (n=81, 42%)</b>	<b>Without AKI (n=114, 58%)</b>	<b>p-value</b>
	<b>Frequency (%); Mean ± SD</b>			
<b>Age</b>	51.39 ± 15.02	56.28 ± 14.12	47.91 ± 14.72	<b>&lt;0.001</b>
<b>Gender</b>				0.147
Male	103 (52.82)	48 (59.26)	55 (48.25)	
Female	92 (47.18)	33 (40.74)	59 (51.75)	
<b>Comorbidities</b>				
Hypertension	89 (45.64)	47 (58.02)	42 (36.84)	<b>0.004</b>
Diabetes Mellitus	41 (21.03)	26 (32.1)	15 (13.16)	<b>0.002</b>
Cardiovascular Disease	24 (12.31)	17 (20.99)	7 (6.14)	<b>0.003</b>
COPD	20 (10.26)	9 (9.88)	12 (10.53)	1.000
	11 (5.64)	5 (6.17)	6 (5.26)	0.765
<b>eGFR by CKD-EPI</b>	85.6 (58 to 103)	50.6 (26 to 70)	98.4 (84 to 112)	<b>&lt;0.001</b>
>90	25 (12.82)	24 (29.63)	1 (0.88)	<b>&lt;0.001</b>
60 to 89	10 (5.13)	10 (12.35)	0	
45 to 59	17 (8.72)	13 (16.05)	4 (3.51)	
30 to 44	53 (27.18)	18 (22.22)	35 (30.70)	
< 30 to >15	90 (46.15)	16 (19.75)	74 (64.91)	
<b>Medication</b>				
Diuretic	43 (22.05)	28 (34.57)	15 (13.16)	<b>0.001</b>
Inotropes	23 (11.79)	17 (20.99)	6 (5.26)	<b>0.001</b>
Antibiotics	2 (1 to 2)	2 (1 to 2)	1 (1 to 2)	0.094
With	178 (91.28)	81 (100)	97 (85.09)	<b>&lt;0.001</b>
Without	17 (8.72)	0	17 (14.91)	
Antiviral	20 (10.26)	9 (11.11)	11 (9.65)	0.813
NSAIDs	13 (6.67)	4 (4.94)	9 (7.89)	0.563
Sedation	1 (0.51)	1 (1.23)	0	0.41
Steroids	80 (41.03)	40 (49.38)	40 (35.09)	0.055
ACEi/ARB	69 (35.48)	33 (40.74)	36 (31.58)	0.224

389

390 ACEi, angiotensin-converting enzyme inhibitors; AKI, acute kidney injury; ARB,  
391 angiotensin II receptor blockers; eGFR by CKD-EPI, estimated glomerular filtration  
392 rate by the Chronic Kidney Disease Epidemiology Collaboration; SD, standard  
393 deviation  
394

395 **Table 2. Urinalysis Results of COVID-19 Confirmed Patients**

	<b>Total (n=195)</b>	<b>With AKI (n=81, 42%)</b>	<b>Without AKI (n=114, 58%)</b>	
<b>Frequency (%); Median (IQR)</b>				
<b><i>Macroscopic</i></b>				
Color				<b>0.655</b>
Yellow	58 (67.44)	34 (69.39)	24 (64.86)	
Light Yellow	13 (15.12)	8 (16.33)	5 (13.51)	
Dark Yellow	11 (12.79)	6 (12.24)	5 (13.51)	
Amber	4 (4.65)	1 (2.04)	3 (8.11)	
Transparency				<b>0.042</b>
Hazy	59 (68.6)	35 (71.43)	24 (64.86)	
Turbid	15 (17.44)	11 (22.45)	4 (10.81)	
Clear	12 (13.95)	3 (6.12)	9 (24.32)	
pH	6 (5 to 6)	6 (5 to 6)	6 (6 to 7)	0.058
Specific Gravity	1.03 (1.02 to 1.03)	1.03 (1.02 to 1.03)	1.02 (1.02 to 1.03)	0.259
<b><i>Chemical tests</i></b>				
Glucose (n=86)				<b>0.190</b>
Negative and Trace	68 (79.07)	36 (73.47)	32 (86.49)	
1	8 (9.3)	7 (14.29)	1 (2.7)	
2	8 (9.3)	5 (10.2)	3 (8.11)	
3	1 (1.16)	1 (2.04)	0	
4	1 (1.16)	0	1 (2.7)	
Protein (n=86)				<b>0.171</b>
Negative and Trace	50 (58.14)	25 (51.02)	25 (67.57)	
1	23 (26.74)	17 (34.69)	6 (16.22)	
2	12 (13.95)	6 (12.24)	6 (16.22)	
3	1 (1.16)	1 (2.04)	0	

<b>Blood (n=81)</b>				<b>0.047</b>
Negative and Trace	68 (83.95)	34 (75.56)	34 (94.44)	
1	2 (2.47)	2 (4.44)	0	
2	4 (4.94)	2 (4.44)	2 (5.56)	
3	6 (7.41)	6 (13.33)	0	
4	1 (1.23)	1 (2.22)	0	
<b>Ketones (n=82)</b>				<b>0.434</b>
Negative and Trace	74 (90.24)	41 (91.11)	33 (89.19)	
1	5 (6.1)	2 (4.44)	3 (8.11)	
2	2 (2.44)	2 (4.44)	0	
3	1 (1.22)	0	1 (2.7)	
<b>Nitrate (n=82)</b>				<b>1.000</b>
Negative and Trace	81 (98.78)	44 (97.78)	37 (100)	
1	1 (1.22)	1 (2.22)	0	
<b>Bilirubin (n=82)</b>				<b>-</b>
Negative and Trace	82 (100)	45 (100)	37 (100)	
<b>Urobilinogen (n=86)</b>				<b>0.515</b>
Negative and Trace	55 (67.07)	30 (66.67)	25 (67.57)	
0.1	23 (28.05)	13 (28.89)	10 (27.03)	
0.2	1 (1.22)	0	1 (2.7)	
1	2 (2.44)	2 (4.44)	0	
2	1 (1.22)	0	1 (2.7)	
<b>Leukocytes (n=82)</b>				<b>0.248</b>
Negative and Trace	79 (96.34)	42 (93.33)	37 (100)	
1	3 (3.66)	3 (6.67)	0	
<b><i>Microscopic</i></b>				
<b>RBC (n=86)</b>				<b>0.227</b>
0 to 5	45 (52.33)	22 (44.9)	23 (62.16)	
6 to 20	23 (26.74)	14 (28.57)	9 (24.32)	
> 20	18 (20.93)	13 (26.53)	5 (13.51)	

<hr/>				
WBC (n=86)				0.509
0 to 5	52 (60.47)	27 (55.1)	25 (67.57)	
6 to 20	24 (27.91)	15 (30.61)	9 (24.32)	
> 20	10 (11.63)	7 (14.29)	3 (8.11)	
<hr/>				
Epithelial Cells (n=86)				0.488
None	5 (5.81)	3 (6.12)	2 (5.41)	
Few/rare	30 (34.88)	18 (36.73)	12 (32.43)	
Occasional/Moderate	44 (51.16)	26 (53.06)	18 (48.65)	
Many	7 (8.14)	2 (4.08)	5 (13.51)	
<hr/>				
Mucus Threads (n=86)				0.150
None	4 (4.65)	1 (2.04)	3 (8.11)	
Few/rare	44 (51.16)	25 (51.02)	19 (51.35)	
Occasional/Moderate	29 (33.72)	20 (40.82)	9 (24.32)	
Many	9 (10.47)	3 (6.12)	6 (16.22)	
<hr/>				
Bacteria (n=86)				<b>0.038</b>
None	1 (1.16)	0	1 (2.7)	
Few/rare	51 (59.3)	24 (48.98)	27 (72.97)	
Occasional/Moderate	27 (31.4)	19 (38.78)	8 (21.62)	
Many	7 (8.14)	6 (12.24)	1 (2.7)	
<hr/>				
Yeast Cells (n=86)				0.622
None	80 (93.02)	47 (95.92)	33 (89.19)	
Few/rare	2 (2.44)	1 (2.04)	1 (2.7)	
Occasional/Moderate	1 (1.16)	0	1 (2.7)	
Many	3 (3.49)	1 (2.04)	2 (5.41)	
<hr/>				
<b><i>Crystals</i></b>				
<hr/>				
Amorphous urates (n=84)				<b>0.001</b>
None	9 (10.71)	4 (8.51)	5 (13.51)	
Few/rare	30 (35.71)	9 (19.15)	21 (56.76)	
Occasional/Moderate	34 (40.48)	26 (55.32)	8 (21.62)	
Many	11 (13.1)	8 (17.02)	3 (8.11)	
<hr/>				

Amorphous phosphate (n=86)	79 (91.86)	45 (91.84)	34 (91.89)	0.682
None	2 (2.33)	1 (2.04)	1 (2.7)	
Few/rare	3 (3.49)	1 (2.04)	2 (5.41)	
Occasional/Moderate	2 (2.33)	2 (4.08)	0	
Many				
<hr/>				
Casts (n=86)				
Coarse granular	9 (10.47)	7 (14.29)	2 (5.41)	0.289
Fine granular	5 (5.81)	1 (2.04)	4 (10.81)	0.160
Hyaline	2 (2.33)	1 (2.04)	1 (2.7)	1.000
WBC	2 (2.33)	1 (2.04)	1 (2.7)	1.000
Waxy	1 (1.16)	1 (2.04)	0	1.000

396 AKI, acute kidney injury; IQR, interquartile range; RBC, red blood cells; WBC, white  
397 blood cells  
398

399 **Table 3. Frequency of Renal Function According to Staging of AKI Based on**  
400 **KDIGO 2012 (n=81)**

	<b>Frequency (%)</b>
AKI stage 1	40 (49.38)
AKI Stage 2	12 (14.81)
AKI Stage 3	29 (35.8)

401 AKI, acute kidney injury; KDIGO, Kidney Disease Improving Global Outcomes

402

403 **Table 4. Assessment of Outcome of Patients With AKI vs. Those Without**

	<b>Total (n=195)</b>	<b>With AKI (n=81, 42%)</b>	<b>Without AKI (n=114, 58%)</b>	<b>p-value</b>
	<b>Frequency (%); Median (IQR)</b>			
<b>Mortality</b>				<b>&lt;0.001</b>
Expired	55 (28.21)	41 (50.62)	14 (12.28)	
Discharged	140 (71.79)	40 (49.38)	100 (87.72)	
<b>Length of Hospital Stay</b>	21 (12 to 27)	20 (8 to 26)	21 (15 to 28)	0.053
<b>Morbidity</b>				
Nasal cannula	74 (47.95)	31 (38.27)	43 (37.72)	1.000
Facemask	28 (14.36)	15 (18.52)	13 (11.4)	0.214
High flow nasal cannula	10 (5.13)	5 (6.17)	5 (4.39)	0.744
Mechanical ventilation	37 (18.97)	26 (32.1)	11 (9.65)	<b>&lt;0.001</b>
<b>Renal replacement therapy</b>				<b>&lt;0.001</b>
Yes	27 (13.85)	25 (30.86)	2 (1.75)	
No	168 (86.15)	56 (69.14)	112 (98.25)	

404 AKI, acute kidney injury; IQR, interquartile range

405




406 **Table 5. Assessment of Outcomes in Patients Based on AKI Stage**

	<b>AKI Stage 1</b>	<b>AKI Stage 2</b>	<b>AKI Stage 3</b>
	<b>(n=40)</b>	<b>(n=12)</b>	<b>(n=29)</b>
	<b>Frequency (%); Median (IQR)</b>		
Mortality			
Expired	15 (37.5)	5 (41.67)	21 (72.41)
Discharged	25 (62.5)	7 (58.33)	8 (27.59)
Length of Hospital Stay	21 (8 to 26)	24 (14 to 30)	10 (4 to 25)
Renal replacement therapy			
Yes	5 (12.5)	2 (16.67)	18 (62.07)
No	35 (87.5)	10 (83.33)	11 (37.93)

407 AKI, acute kidney injury; IQR, interquartile range

408

409



Figure